In breast cancer, dysregulated p53 expression signatures are a better predictor of outcome and chemotherapy response than TP53 mutation [2, 3], suggesting that alternative molecular mechanisms may compromise p53 function. The gene discussed is TP53; the disease is breast carcinoma.